PRPF4B

Across TCGA pan-cancer cohorts, PRPF4B Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated PRPF4B data layer compared with 24 for mass-spec protein and 4 for mass-spec protein.

The strongest signal is observed in cervical squamous cell carcinoma and endocervical adenocarcinoma (CESC), where higher PRPF4B Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated PRPF4B expression acts as an unfavorable survival marker, although some lineages such as COAD show a favorable association.

CESC, ESCA, and COAD are the cancer types where PRPF4B Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CESC	OS	Median	All	0.094	0.587	.027	6	view →
ESCA	OS	Median	II,III,IV	0.321	0.685	.035	6	view →
COAD	DFS	Median	All	1.000	0.502	.049	1	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

PRPF4B–CESC (OS)

Open the CESC breakdown →